Could we be next? Philippe Dro, PharmD, MBA
Director
Dr. Philippe Dro joined the MedMira Board in 2015. Most recently Dr. Dro was the Chief Executive Officer and member of the supervisory board of GlycoVaxyn AG, a Swiss biotechnology company in the vaccine sector, which was acquired earlier this year by GlaxoSmithKline. Previous to GlycoVaxyn, Dr. Dro was Chairman and Chief Executive Officer of Endoart SA, a medtech company developing telemetric driven implants for cardiac disease and obesity, which was sold to Allergan, Inc. in 2007. Dr. Dro earned a PharmD from University of Grenoble (France) and an MBA jointly from Ecole Superieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
So he has been involved in buyouts with his last two gigs. He was brought on for a reason IMO. Now with Allergan on a buying spree, can we be a prime target? fda any day now, new found interest in the stock....thoughts?
https://www.streetinsider.com/Mergers+and+Acquisitions/Allergan+(AGN)+is+on+A+Major+Buying+Spree...+And+Its+Just+Getting+Started/12056002.html